GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
‘A very proud moment’: J’Oli Co-Founder celebrates new Cypriot outlet
Jean Paul Cascun says new Paphos outlet is 'only the beginning'.
Stefan Riolo appointed Executive Director of Clearflowplus
Stefan Riolo succeeds David Sacco in the executive role.
Beyond the boardroom: How St John’s Co-Cathedral is redefining corporate engagement
The country's mix of heritage venues and close-knit business community means familiar settings can be transformed into something genuinely memorable.
Sawadee Valletta! Iniala brings Thai family-style dining to Malta
Led by celebrity chef Ian Kittichai, Anaalā takes diners on a journey across Thailand with four rotating menus.
